Yi Gong1, Yan Li1, Qian Sun1. 1. Department of Gastroenterology, Shengjing Hospital, China Medical University Shenyang, China.
Abstract
OBJECTIVE: Gastric colonization by Helicobacter pylori is linked to a host of diseases, but eradication rates have declined in recent years. Some experimental studies suggest that probiotics may inhibit growth of H. pylori. This investigation was conducted to assess the impact of probiotics on both efficacy and tolerability of triple therapy to eradicate H. pylori. METHODS: PubMed, Web of Science, and the Cochrane Collaboration were searched for relevant articles published through August 31, 2014. All analytics relied on commercially available software (Stata 11). RESULTS: Twenty-three studies (N = 3900) qualified for meta-analysis. Pooled H. pylori eradication rates for triple therapy used alone and with added probiotics were 1464/2026 (72.26%; 95% CI, 67.66%-74.13) and 1513/1874 (80.74%; 95% CI, 74.68%-82.76%), respectively (odds ratio [OR] = 0.58; 95% CI, 0.50-0.68). Loss of appetite was similar in both groups (OR = 0.94; 95% CI, 0.61-1.45), but most adverse events (nausea, diarrhea, epigastric pain, vomiting, taste distortion, and skin rash) were mitigated through addition of probiotics. Publication bias was not evident, as indicated by Begg's and Egger's tests. CONCLUSIONS: Probiotics may improve the efficacy of triple therapy in eradicating gastric H. pylori and alleviate most treatment-related adverse events.
OBJECTIVE: Gastric colonization by Helicobacter pylori is linked to a host of diseases, but eradication rates have declined in recent years. Some experimental studies suggest that probiotics may inhibit growth of H. pylori. This investigation was conducted to assess the impact of probiotics on both efficacy and tolerability of triple therapy to eradicate H. pylori. METHODS: PubMed, Web of Science, and the Cochrane Collaboration were searched for relevant articles published through August 31, 2014. All analytics relied on commercially available software (Stata 11). RESULTS: Twenty-three studies (N = 3900) qualified for meta-analysis. Pooled H. pylori eradication rates for triple therapy used alone and with added probiotics were 1464/2026 (72.26%; 95% CI, 67.66%-74.13) and 1513/1874 (80.74%; 95% CI, 74.68%-82.76%), respectively (odds ratio [OR] = 0.58; 95% CI, 0.50-0.68). Loss of appetite was similar in both groups (OR = 0.94; 95% CI, 0.61-1.45), but most adverse events (nausea, diarrhea, epigastric pain, vomiting, taste distortion, and skin rash) were mitigated through addition of probiotics. Publication bias was not evident, as indicated by Begg's and Egger's tests. CONCLUSIONS: Probiotics may improve the efficacy of triple therapy in eradicating gastric H. pylori and alleviate most treatment-related adverse events.
Authors: J A da Silva Medeiros; T M F O Gonçalves; L Boyanova; M I de Correia Pereira; J N da Silva Paiva de Carvalho; A M de Sousa Pereira; A M Silvério Cabrita Journal: Eur J Clin Microbiol Infect Dis Date: 2011-01-05 Impact factor: 3.267
Authors: Ruggiero Francavilla; Lorenzo Polimeno; Antonella Demichina; Giovanni Maurogiovanni; Beatrice Principi; Giuseppe Scaccianoce; Enzo Ierardi; Francesco Russo; Giuseppe Riezzo; Alfredo Di Leo; Luciano Cavallo; Antonio Francavilla; James Versalovic Journal: J Clin Gastroenterol Date: 2014 May-Jun Impact factor: 3.062
Authors: Sung Keun Park; Dong Il Park; Joong Sub Choi; Mun Su Kang; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim Journal: Hepatogastroenterology Date: 2007 Oct-Nov